Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction involving Dr. P J T Vallance, a Person Discharging Managerial Responsibilities. On January 21, 2016, GSK was advised that Dr. Vallance's Connected Person, Dr. S Dexter, acquired 404 GSK Ordinary Shares. This acquisition occurred at a price of 1,373.50 pence per share following the re-investment of the dividend paid to shareholders on January 14, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the share transaction described above.
Investor Verification Points
- Verify the total shareholding of Dr. P J T Vallance and Dr. S Dexter following this transaction.
- Confirm the dividend reinvestment plan details for the January 14, 2016 payment.
- Check for any other concurrent director or connected person transactions not listed in this specific notification.